Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism GABRA5 modulators(Gamma-aminobutyric acid A receptor alpha-5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Damona Pharmaceuticals, Inc.Startup |
Active Organization Damona Pharmaceuticals, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | CA | Damona Pharmaceuticals, Inc.Startup | 15 Jun 2024 |
Cognition Disorders | Preclinical | CA | Damona Pharmaceuticals, Inc.Startup | 15 Jun 2024 |
Depressive Disorder, Major | Preclinical | CA | Damona Pharmaceuticals, Inc.Startup | 15 Jun 2024 |
Schizophrenia | Preclinical | CA | Damona Pharmaceuticals, Inc.Startup | 15 Jun 2024 |